MAPT and Alzheimer disease: Thus, cis, but not trans, p-tau is a likely pathogenic form of tau in MCI and AD and the development of humanised antibodies directed against pathogenic cis p-tau could be useful for the early diagnosis and treatment of AD, TBI and CTE.